• Vidofludimus is a novel oral immunomodulator with substantial activity in various autoimmune models that is currently clinically developed for inflammatory bowel disease (IBD). Induction of apoptosis in mucosal T cells from IBD patients is a relevant therapeutic mechanism since several effective IBD drugs like azathioprine, infliximab, or sulphasalazine were shown to induce apoptosis in activated T cells ( 
Introduction

Vidofludimus induces p53-mediated apoptosis in activated T cells and inhibits IL-17A and IL-17F expression decoupled from lymphocyte proliferation
• Vidofludimus is a potent inducer of apoptosis in PHA activated T cells and Jurkat cells, comparable to reference compound 6-MP (active metabolite of azathioprine, Fig. 1A and 1B) . The active metabolite of leflunomide (AA771726) was less active, particularly in Jurkat cells (Fig. 1B and 1C) . G1/S arrest ( Fig. 1D and 1E ) and strong accumulation of p53 (Fig. 1F) by vidofludimus precede apoptosis induction.
• Vidofludimus inhibits production of IL-17AA/AF and IL-17FF in a dose-dependent fashion with IC 50 values between 3 and 10 µM ( Fig. 2A) . This correlates well with reduced gene expression patterns for IL-17 subtypes 20 h after PHA stimulation (Fig. 2B ).
• This effect on cytokine expression is decoupled from its effect on T cell proliferation as significant inhibition of IL-17 production is observed already 24 h after stimulation whereas inhibition of T cell proliferation by vidofludimus as judged by BrdU incorporation is not detectable earlier than 48 h after activation ( 
Results
• Vidofludimus has been shown to strongly induce cell cycle arrest, p53 accumulation and subsequent apoptosis in activated T cells and, thus, possesses crucial features of an effective IBD drug.
• In addition, vidofludimus inhibits production of both IL-17A and IL-17F and, therefore, is capable of inhibiting this important family of pro-inflammatory cytokines, especially IL-17F which has been described to be of particular relevance for IBD.
• We could demonstrate that inhibition of IL-17 family cytokines by vidofludimus is decoupled from its effects on T cell proliferation. This observation has been confirmed by experiments in a TNBSinduced rat colitis model where the additional administration of uridine to vidofludimus had an influence on most macroscopic and histological colitis parameters while IL-17 and STAT3 expression was not affected by the addition of uridine (data presented elsewhere).
• The combination of all these effects apparently contributes substantially to the beneficial effects of vidofludimus observed in IBD patients as previously reported. 
